1
|
Zang L, Baharlooeian M, Terasawa M, Shimada Y, Nishimura N. Beneficial effects of seaweed-derived components on metabolic syndrome via gut microbiota modulation. Front Nutr 2023; 10:1173225. [PMID: 37396125 PMCID: PMC10311452 DOI: 10.3389/fnut.2023.1173225] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Accepted: 04/10/2023] [Indexed: 07/04/2023] Open
Abstract
Metabolic syndrome comprises a group of conditions that collectively increase the risk of abdominal obesity, diabetes, atherosclerosis, cardiovascular diseases, and cancer. Gut microbiota is involved in the pathogenesis of metabolic syndrome, and microbial diversity and function are strongly affected by diet. In recent years, epidemiological evidence has shown that the dietary intake of seaweed can prevent metabolic syndrome via gut microbiota modulation. In this review, we summarize the current in vivo studies that have reported the prevention and treatment of metabolic syndrome via seaweed-derived components by regulating the gut microbiota and the production of short-chain fatty acids. Among the surveyed related articles, animal studies revealed that these bioactive components mainly modulate the gut microbiota by reversing the Firmicutes/Bacteroidetes ratio, increasing the relative abundance of beneficial bacteria, such as Bacteroides, Akkermansia, Lactobacillus, or decreasing the abundance of harmful bacteria, such as Lachnospiraceae, Desulfovibrio, Lachnoclostridium. The regulated microbiota is thought to affect host health by improving gut barrier functions, reducing LPS-induced inflammation or oxidative stress, and increasing bile acid production. Furthermore, these compounds increase the production of short-chain fatty acids and influence glucose and lipid metabolism. Thus, the interaction between the gut microbiota and seaweed-derived bioactive components plays a critical regulatory role in human health, and these compounds have the potential to be used for drug development. However, further animal studies and human clinical trials are required to confirm the functional roles and mechanisms of these components in balancing the gut microbiota and managing host health.
Collapse
Affiliation(s)
- Liqing Zang
- Graduate School of Regional Innovation Studies, Mie University, Tsu, Mie, Japan
- Mie University Zebrafish Research Center, Mie University, Tsu, Mie, Japan
| | - Maedeh Baharlooeian
- Department of Marine Biology, Faculty of Marine Science and Oceanography, Khorramshahr University of Marine Science and Technology, Khorramshahr, Iran
| | | | - Yasuhito Shimada
- Mie University Zebrafish Research Center, Mie University, Tsu, Mie, Japan
- Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Mie, Japan
- Department of Bioinformatics, Mie University Advanced Science Research Promotion Center, Tsu, Mie, Japan
| | - Norihiro Nishimura
- Graduate School of Regional Innovation Studies, Mie University, Tsu, Mie, Japan
- Mie University Zebrafish Research Center, Mie University, Tsu, Mie, Japan
| |
Collapse
|
2
|
Ai S, Li Y, Tao J, Zheng H, Tian L, Wang Y, Wang Z, Liu WJ. Bibliometric visualization analysis of gut-kidney axis from 2003 to 2022. Front Physiol 2023; 14:1176894. [PMID: 37362429 PMCID: PMC10287975 DOI: 10.3389/fphys.2023.1176894] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Accepted: 05/31/2023] [Indexed: 06/28/2023] Open
Abstract
Background: The gut-kidney axis refers to the interaction between the gastrointestinal tract and the kidneys, and its disorders have become increasingly important in the development of kidney diseases. The aim of this study is to identify current research hotspots in the field of the gut-kidney axis from 2003 to 2022 and provide guidance for future research in this field. Methods: We collected relevant literature on the gut-kidney axis from the Web of Science Core Collection (WoSCC) database and conducted bibliometric and visualization analyses using biblioshiny in R-Studio and VOSviewer (version 1.6.16). Results: A total of 3,900 documents were retrieved from the WoSCC database. The publications have shown rapid expansion since 2011, with the greatest research hotspot emerging due to the concept of the "intestinal-renal syndrome," first proposed by Meijers. The most relevant journals were in the field of diet and metabolism, such as Nutrients. The United States and China were the most influential countries, and the most active institute was the University of California San Diego. Author analysis revealed that Denise Mafra, Nosratola D. Vaziri, Fouque, and Denis made great contributions in different aspects of the field. Clustering analysis of the keywords found that important research priorities were "immunity," "inflammation," "metabolism," and "urinary toxin," reflecting the basis of research in the field. Current research frontiers in the field include "hyperuricemia," "gut microbiota," "diabetes," "trimethylamine n-oxide," "iga nephropathy," "acute kidney injury," "chronic kidney disease," "inflammation," all of which necessitate further investigation. Conclusion: This study presents a comprehensive bibliometric analysis and offers an up-to-date outlook on the research related to the gut-kidney axis, with a specific emphasis on the present state of intercommunication between gut microbiota and kidney diseases in this field. This perspective may assist researchers in selecting appropriate journals and partners, and help to gain a deeper understanding of the field's hotspots and frontiers, thereby promoting future research.
Collapse
Affiliation(s)
- Sinan Ai
- Renal Research Institution of Beijing University of Chinese Medicine, Beijing, China
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Yake Li
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
| | - JiaYin Tao
- Renal Research Institution of Beijing University of Chinese Medicine, Beijing, China
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Huijuan Zheng
- Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| | - Lei Tian
- Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
| | - Yaoxian Wang
- Renal Research Institution of Beijing University of Chinese Medicine, Beijing, China
| | - Zhen Wang
- Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
| | - Wei Jing Liu
- Renal Research Institution of Beijing University of Chinese Medicine, Beijing, China
- Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing, China
| |
Collapse
|
3
|
Yu Y, Lu Q, Chen F, Wang S, Niu C, Liao J, Wang H, Chen F. Serum untargeted metabolomics analysis of the mechanisms of evodiamine on type 2 diabetes mellitus model rats. Food Funct 2022; 13:6623-6635. [PMID: 35635367 DOI: 10.1039/d1fo04396j] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Evodiamine (EVO) is an alkaloid extracted from Evodia rutaecarpa and has various pharmacological activities, including hypolipidemic, anti-inflammatory, anti-infective, and antitumor effects. However, the therapeutic effects of EVO on type 2 diabetes mellitus (T2DM) and the possible mechanisms remain unknown. In this study, we used a T2DM rat model using a high-fat diet (HFD) combined with streptozotocin (STZ) injections followed by treatment with EVO. First, we evaluated the therapeutic effects of EVO on T2DM rats, following which we evaluated the anti-inflammatory and anti-oxidative effects of EVO on T2DM rats. Finally, we analyzed the metabolic regulatory mechanism of EVO in T2DM rats using an untargeted metabolomics approach. The results showed that EVO treatment alleviated the hyperglycemia, hyperlipidemia, insulin resistance (IR), and pathological changes of the liver, pancreas and kidneys in T2DM rats. Moreover, EVO treatment ameliorated the oxidative stress and decreased the serum levels of pro-inflammatory cytokines in T2DM model rats. Serum untargeted metabolomics analysis indicated that the EVO treatment affected the levels of 26 metabolites, such as methionine, citric acid, cholesterol, taurocholic acid, pilocarpine, adrenic acid, and other metabolites. These metabolites were mainly related to the amino sugar and nucleotide sugar metabolism, arginine biosynthesis, arginine and proline metabolism, glutathione metabolism, and tryptophan metabolism pathways. In conclusion, EVO can reduce blood glucose and improve oxidative stress and inflammatory response in T2DM rats. These functions are related to the regulation of amino sugar and nucleotide sugar metabolism, arginine biosynthesis, arginine and proline metabolism, glutathione metabolism, and tryptophan metabolism pathways.
Collapse
Affiliation(s)
- Yuejie Yu
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Qinyan Lu
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Feng Chen
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Shangli Wang
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Chunxiang Niu
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Jiabao Liao
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| | - Hongwu Wang
- Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
| | - Fengjuan Chen
- Jiaxing Hospital of Traditional Chinese Medicine, Jiaxing 314001, China.
| |
Collapse
|
4
|
Wang T, Zhang D, Guoc C, Zhu W. Novel PARP inhibitor DDPF-20 induces DNA damage and inhibits angiogenesis through the PI3K/Akt/VEGF pathway. Anticancer Agents Med Chem 2022; 22:2468-2476. [PMID: 35189801 DOI: 10.2174/1871520622666220221115007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2021] [Revised: 11/15/2021] [Accepted: 12/17/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Poly (ADP-ribose) polymerase (PARP) plays a key role in DNA damage repair. A novel compound (E)-N'-(2,3-dibromo-4,5-dihydroxyphenyl)-N-(phenylcarbamothioyl)formimidamide (DDPF-20) with excellent PARP inhibitory activity was synthesized. OBJECTIVE In this study, we aimed to clarify the mechanism of the novel PARP inhibitor DDPF-20 against lung cancer by inducing DNA damage and inhibiting angiogenesis. METHOD The cytotoxic effect of DDPF-20 on A549 cell line was determined with an MTT assay. Cell cycle and apoptosis was determined by flow cytometer. The γH2AX foci was detected by immunofluorescence. Capillary-like tube formation assay and chick chorioallantoic membrane (CAM) assay was used to detect angiogenesis inhibitory effect of DDPF-20. The expressions of related proteins were detected by western blot. The anticancer activity of DDPF-20 in vivo was also detected. RESULTS With an IC50 value of 52.42 ± 15.13 nM, DDPF-20 inhibited the proliferation, induced G2/M cycle arrest and induced apoptosis of human lung cancer A549 cells. Further research showed that DDPF-20 induced DNA double-strand breaks (DSBs). Interestingly, DDPF-20 inhibited the tube formation of HUVEC cells, as well as inhibited the neovascularization of CAM, proving the angiogenesis inhibitory ability of DDPF-20. Mechanism studies proved that DDPF-20 inhibited the PI3K/Akt/VEGF signaling pathway. In an in vivo study, DDPF-20 inhibited tumor growth of an A549 xenograft. Analysis of the molecular mechanism underlying this effect revealed that the PI3K/Akt/VEGF pathway was involved in DDPF-20-induced cell death and inhibited angiogenesis in vivo. CONCLUSION This study suggested that the novel PARP inhibitor DDPF-20 may have therapeutic potential in treating lung cancer.
Collapse
Affiliation(s)
- Tian Wang
- Department of Thoracic Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, 266035, China
| | - Dong Zhang
- Department of Thoracic Surgery, Pingdu People\'s Hospital, Pingdu, Shandong, 266700, China
| | - Chuanlong Guoc
- Department of Pharmacy, College of Chemical Engineering, Qingdao University of Science and Technology, Qingdao, Shandong 266042, China
| | - Wenyong Zhu
- Department of Thoracic Surgery, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, Shandong, 266035, China
| |
Collapse
|
5
|
Li Z, Nie L, Li Y, Yang L, Jin L, Du B, Yang J, Zhang X, Cui H, Luobu O. Traditional Tibetan Medicine Twenty-Five Wei’er Tea Pills Ameliorate Rheumatoid Arthritis Based on Chemical Crosstalk Between Gut Microbiota and the Host. Front Pharmacol 2022; 13:828920. [PMID: 35222043 PMCID: PMC8867225 DOI: 10.3389/fphar.2022.828920] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Accepted: 01/17/2022] [Indexed: 12/13/2022] Open
Abstract
Twenty-Five Wei’er Tea Pills (TFP), a traditional Tibetan medicine, has shown to have a promising therapeutic effect in patients with Rheumatoid arthritis (RA), as well as being safe. Nonetheless, there have been limited pharmacological studies that have explored this therapeutic option. As gut microbiota has been proven to have a critical role in the pathogenesis of RA, this study aims to explore and reveal relevant ways by which TFP interacts with the chemical crosstalk between the gut microbiome and its host. 16S rRNA sequencing, combined with un-targeted metabolomics, were conducted on collagen-induced arthritis (CIA) rats. CIA model rats treated with TFP showed significant improvement in weight gain, pathological phenomena in joints, as well as decreased serum levels of TNF-α, IL-6 and increased level of IL-4 and IL-10. Significant dysfunction in the gut microbiome and alteration in serum metabolites were observed in CIA model rats, which were restored by TFP treatment. Coherence analysis indicated that TFP modulated the pathways of histidine metabolism, phenylalanine metabolism, alanine, aspartate, glutamate metabolism, amino sugar and nucleotide sugar metabolism owing to the abundances of Lactobacillus, Bacteroides, Prevotellaceae_UCG-001 and Christensenellaceae_R-7_group in the gut microflora. The corresponding metabolites involved L-histidine, histamine, phenylethylamine, asparagine, L-aspartic acid, D-fructose 1-phosphate, D-Mannose 6-phosphate, D-Glucose 6-phosphate, and Glucose 1-phosphate. In conclusion, this study reveals the ameliorative effects of TFP on RA through the chemical crosstalk that exists between the gut microbiota and its host, and also further enriches our understandings of the pathogenesis of RA.
Collapse
Affiliation(s)
- Zixuan Li
- Department of Basic Medicine, Medical College of Tibet University, Lhasa, China
| | - Lijuan Nie
- Department of Pharmacy, Medical College of Tibet University, Lhasa, China
| | - Yong Li
- Institute of Oxygen Supply, Center of Tibetan Studies (Everest Research Institute), Tibet University, Lhasa, China
| | - Lu Yang
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Lulu Jin
- Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Baozhong Du
- Department of Basic Medicine, Medical College of Tibet University, Lhasa, China
| | - Juan Yang
- Department of Basic Medicine, Medical College of Tibet University, Lhasa, China
| | - Xulin Zhang
- Second Affiliated Hospital of University of South China, Hengyang, China
| | - Huantian Cui
- Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao, China
- *Correspondence: Ouzhu Luobu, ; Huantian Cui,
| | - Ouzhu Luobu
- Medical College of Tibet University, Lhasa, China
- Affiliated Fukang Hospital of Tibet University, Lhasa, China
- *Correspondence: Ouzhu Luobu, ; Huantian Cui,
| |
Collapse
|
6
|
Zheng QX, Jiang XM, Wang HW, Ge L, Lai YT, Jiang XY, Chen F, Huang PP. Probiotic supplements alleviate gestational diabetes mellitus by restoring the diversity of gut microbiota: a study based on 16S rRNA sequencing. J Microbiol 2021; 59:827-839. [PMID: 34382149 DOI: 10.1007/s12275-021-1094-8] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 06/29/2021] [Accepted: 07/07/2021] [Indexed: 01/09/2023]
Abstract
Probiotics effectively prevent and improve metabolic diseases such as diabetes by regulating the intestinal microenvironment and gut microbiota. However, the effects of probiotics in gestational diabetes mellitus are not clear. Here, we showed that probiotic supplements significantly improved fasting blood glucose in a gestational diabetes mellitus rat model. To further understand the mechanisms of probiotics in gestational diabetes mellitus, the gut microbiota were analyzed via 16S rRNA sequencing. We found that compared with the normal pregnant group, the gestational diabetes mellitus rats had decreased diversity of gut microbiota. Moreover, probiotic supplementation restored the diversity of the gut microbiota in gestational diabetes mellitus rats, and the gut microbiota structure tended to be similar to that of normal pregnant rats. In particular, compared with gestational diabetes mellitus rats, the abundance of Firmicutes and Actinobacteria was higher after probiotic supplementation. Furthermore, activating carbohydrate metabolism and membrane transport pathways may be involved in the potential mechanisms by which probiotic supplements alleviate gestational diabetes mellitus. Overall, our results suggested that probiotic supplementation might be a novel approach to restore the gut microbiota of gestational diabetes mellitus rats and provided an experimental evidence for the use of probiotic supplements to treat gestational diabetes mellitus.
Collapse
Affiliation(s)
- Qing-Xiang Zheng
- Fujian Maternity and Child Health Hospital Affiliated to Fujian Medical University, Fuzhou, 350000, P. R. China
| | - Xiu-Min Jiang
- Fujian Maternity and Child Health Hospital Affiliated to Fujian Medical University, Fuzhou, 350000, P. R. China.
| | - Hai-Wei Wang
- Fujian Maternity and Child Health Hospital Affiliated to Fujian Medical University, Fuzhou, 350000, P. R. China
| | - Li Ge
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, P. R. China
| | - Yu-Ting Lai
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, P. R. China
| | - Xin-Yong Jiang
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, P. R. China
| | - Fan Chen
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, P. R. China
| | - Ping-Ping Huang
- Fujian University of Traditional Chinese Medicine, Fuzhou, 350122, P. R. China
| |
Collapse
|